Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

pHyph

Financiado

Cerrado

Breakthrough dual-action OTC tablet for treatment and prevention of both bacteri...

Breakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis "There is a large unmet medical need for an efficient and highly accessible solution that can simultaneously treat and prevent BV and VVC, while removing the abuse of antibiotic and antimycotic drugs to avoid further antimicrobial... ver más

31/07/2026

GEDEA BIOTECH AB

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

GEDEA BIOTECH AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-01

HORIZON-EIC-2023-ACCELERATOROPEN-01: EIC Accelerator Open 2023 Scope:The EIC Accelerator Open has no predefined thematic priorities and is open to proposals in any...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

GEDEA BIOTECH AB

Lider

Proyectos interesantes

NEFERTITI

Medical Technol...

Biotechnology

5M€ Cerrado

NEFERTITI

Medical Technol...

Biotechnology

71K€ Cerrado

PID2020-117983RB-I00

Medical Technol...

Public Health

132K€ Cerrado

MINERVA

Medical Technol...

Data Science

185K€ Cerrado

Avodes-Biotech

Medical Technol...

Biotechnology

75K€ Cerrado

PDC2021-121808-I00

Medical Technol...

Microbiology

144K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 27 meses Fecha Inicio: 2024-04-01
Fecha Fin: 2026-07-31

Líder del proyecto

GEDEA BIOTECH AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "There is a large unmet medical need for an efficient and highly accessible solution that can simultaneously treat and prevent BV and VVC, while removing the abuse of antibiotic and antimycotic drugs to avoid further antimicrobial resistance. The inefficacy of current solutions is demonstrated by the huge burden that BV/VCC bring to the society in terms of economic expenses (more than €3.8Bn annually), preterm births (5.4M per year), the huge prevalence of both diseases (more than 500M cases per year) and the deteriorated QoL for women. Gedea has developed pHyph, a patented pessary that due to its safe profile will be highly accessible as a first line OTC solution. pHyph is an antimicrobial-free dual solution with a new mode of action that targets both the treatment and prevention of BV and VVC, without the need of pathogen identification. pHyph will be commercialized as an OTC product in pharmacies and drug stores – where 90% of women with VI look for a treatment to the infection. The business model targeted for pHyph is a well-established and successful B2B2C model for this type of product. Our business model is highly scalable via planned partnerships with distributors and pharma companies, that will facilitate accelerated commercial deployment & scale up of our business throughout Europe & beyond. Gedea core team is composed by 9 persons with over 250 years of experience combined, including experts in clinical research, bioorganic chemistry, regulatory affairs, marketing, and business development. The company received the award ""Rapidus Company of the Year"" and appeared on Labiotech's list ""The 20 European Biotech Companies to Watch in 2022"".During this project, Gedea will perform the necessary clinical trials, CE-Mark Certification and pre-market activities to commercialize pHyph (TRL 9 by 2026). In order to do so, Gedea requires an estimated expenditure of €11.9M, which is requested to the EIC through both Grant and Equity fund."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores